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ABSTRACT Previously, we used cDNA expression
profiling to identify genes associated with glucocorticoid
(Gc) sensitivity. We now identify which of these directly
influence Gc action. Interferon-inducible protein 16
(IFI16), bone morphogenetic protein receptor type II
(BMPRII), and regulator of G-protein signaling 14
(RGS14) increased Gc transactivation, whereas sialyltrans-
ferase 4B (SIAT4B) had a negative effect. Amyloid  (A4)
precursor-protein binding, family B, member 1 (APBB1/
Fe65) and neural cell expressed developmentally down-
regulated 9 (NEDD9) were without effect. Only IFI16
potentiated Gc repression of NF-B. In addition, IFI16
affected basal expression, and Gc induction of endoge-
nous target genes. IFI16 did not affect glucocorticoid
receptor (GR) expression, ligand-dependent repression
of GR expression, or the ligand-dependent induction of
GR phosphorylation on Ser-211 or Ser-203. Coimmuno-
precipitation revealed an interaction, suggesting that IFI16
modulation of GR function is mediated by protein crosstalk.
Transfection analysis with GR mutants showed that the
ligand-binding domain of GR binds IFI16 and is the target
domain for IFI16 regulation. Analysis of human lung
sections identified colocalization of GR and IFI16, sug-
gesting a physiologically relevant interaction. We demon-
strate that IFI16 is a novel modulator of GR function and
show the importance of analyzing variation in Gc sensitiv-
ity in humans, using appropriate technology, to drive
discovery.—Berry, A., Matthews, L. Jangani, M., Plumb,
J., Farrow, S., Buchan, N., Wilson, P. A., Singh, D., Ray,
D., W., Donn, R. P. Interferon-inducible factor 16 is a
novel modulator of glucocorticoid action. FASEB J. 24,
1700–1713 (2010). www.fasebj.org
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Glucocorticoids (Gcs) exert diverse effects on
virtually all cell types and tissues. Changes in tissue
sensitivity to Gcs can result in pathological states (1, 2).
Hypersensitivity to Gcs may result in metabolic diseases
such as visceral obesity-related insulin resistance and
ischemic heart disease (3). Resistance or insensitivity to
Gcs occurs within inflamed tissues and insensitivity to
the therapeutic properties of exogenous Gcs arises (4).
This limits the use of Gcs in the management of diseases
such as rheumatoid arthritis, inflammatory bowel dis-
ease, and asthma. Furthermore, certain pathological
conditions such as small cell lung cancer and chronic
obstructive pulmonary disease (COPD) are profoundly
steroid-resistant (5, 6). The response to Gcs is known to
vary greatly among individuals within a population
(7–10). The glucocorticoid receptor (GR) is a ubiqui-
tous intracellular receptor that mediates the actions of
Gcs and polymorphism of the GR contributes, in part,
to variations in Gc sensitivity (10, 11). Understanding
the genetic factors that influence Gc sensitivity is cru-
cial for elucidating the mechanisms responsible for
resistance and also for the development of more spe-
cific treatment regimens.
We have previously used microarray technology for
transcriptome profiling of lymphocytes from a healthy
cohort and identified a panel of discriminatory genes that
showed small but significant changes in expression be-
tween Gc-sensitive and Gc-resistant groups (7). The aim of
the current study was to identify novel genes capable of
influencing Gc sensitivity by determining the effects of the
genes, identified by microarray, in model cell systems on
GR function. Of the 20 discriminating genes originally
reported, a proportion were predicted simply to be acting
as markers and only some to directly influence Gc action.
In an attempt to prioritize genes for further in vitro
evaluation a combination of standard literature searches
and systems biology informatics was used. Data-mining
informatics allows “hypothesis-free” interactions to be
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identified (12). Predicting the functional effects of our
genes of interest from such database mining, combined
with searching for potential interactions with a GR
signaling pathway, may provide an efficient screening
process before individual gene expression studies in
vitro, using simple reporter gene validation. Finally, we
sought interactions between selected gene products
and the GR itself to provide mechanistic insights.
MATERIALS AND METHODS
Plasmids
TAT3-luciferase (Luc), which contains 3 copies of the glu-
cocorticoid response element (GRE) from the tyrosine amino
transferase plasmid, was a kind gift from Professor Keith
Yamamoto (University of California, San Francisco, CA, USA)
and Dr. Jorge Iniguez-Lluhi (University of Michigan Medical
School, Ann Arbor, MI, USA). The NRE-Luc reporter con-
struct contains 5 copies of an NF-B response element
(Stratagene, La Jolla, CA, USA).
The human wild-type GR in pcDNA3 vector has been
described previously (13). Two deletion constructs, GR F1,
which lacks aa 77-262, and GR N500, which lacks aa 500-777,
were prepared from the human GR plasmid by restriction
enzyme digestion.
The SRC2 expression vector, in a pcDNA3 vector backbone,
was a kind gift from Dr. Julie Stimmel (GlaxoSmithKline,
Research Triangle Park, NC, USA). Full-length bone morpho-
genetic protein receptor type II (BMPRII), amyloid  (A4)
precursor-protein binding, family B, member 1 (APBB1/Fe65),
interferon-inducible protein 16 (IFI16), sialyltransferase 4B
(SIAT4B), and regulator of G-protein signaling 14 (RGS14)
cDNAs cloned into the CMV-SPORT6 vector using NotI/SalI
restriction sites were obtained from Geneservice (Cambridge,
UK). Empty vector control was obtained by cleaving the IFI16
insert out of CMV-SPORT6 using NotI/SalI and religating the
vector. Neural cell expressed developmentally down-regulated 9
(NEDD9) cDNA was obtained from the German Resource
Center for Genome Research (http://www.imagenes-bio.de).
Renilla (sea pansy) luciferase plasmid was used to correct for
transfection efficiency (Promega, Southampton, UK). The control
TAT3GRE plasmid was generated by cleaving the 3 GREs from
the TAT3-Luc vector backbone with SalI/XhoI restriction enzymes.
Antibodies
The following antibodies were used: anti-GR (mouse, clone 41)
from BD Biosciences (San Jose, CA, USA); anti-phospho (Ser-
211)-GR from Cell Signaling Technology Inc. (Danvers, MA,
USA); anti-phospho (Ser-203)-GR and anti-phospho (Ser-
226)-GR from Abcam Inc. (Cambridge, MA, USA); anti-GR
(rabbit, H-300) and anti-IFI16 (rabbit and mouse) from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA); anti-tubulin
from Sigma-Aldrich (St. Louis, MO, USA); anti-human CD3
(clone PS1) from Vision Biosystems, Newcastle, UK); anti-
human CD20 (clone L26) from Vector Laboratories, Peterbor-
ough, UK); and horseradish peroxidase-conjugated anti-
mouse and anti-rabbit from GE Healthcare (Little Chalfont,
UK). Fluorophore-conjugated (Alexa Fluor 546, 568, and
488) anti-mouse and anti-rabbit antibodies were from Invitro-
gen (Paisley, UK).
Bioinformatics
To complete the bioinformatics analysis, two knowledge base
resources were queried: the Ingenuity Knowledge Base (12)
and an interaction repository, which is based on cpath (14)
and includes interactions curated by GeneGo (http://www.
genego.com) and Ingenuity. Networks retrieved from the
latter were visualized using Cytoscape (15). Both resources
were queried using established network searching algorithms
to infer how the derived differential expression data may
interact with established Gc pathways. Based on these analy-
ses, it was possible to direct the described confirmatory
experiments detailed in the Results section.
Cell culture
Human epithelial carcinoma (HeLa) and human embryonic
kidney (HEK) cells were obtained from the European Collec-
tion of Cell Cultures (Salisbury, UK) and maintained in
DMEM supplemented with GlutaMAX I and 10% FCS (In-
vitrogen) in a humidified atmosphere of 5% CO2 at 37°C.
Reporter gene assay
Cells were cotransfected with 2 g of firefly luciferase (TAT3-
Luc, NRE-Luc) and 0.5 g of Renilla luciferase reporter
together using FuGENE 6 (3 l/g of DNA; Roche Diagnos-
tics, Indianapolis, IN, USA). For some experiments, cells were
also transfected with 0.6 or 1.2 g of coactivator or an empty
expression vector control or 1 g of wild-type human GR
(GR), GR AF1, or GR N500 expression plasmids. After
24 h, cells were transferred to medium containing charcoal
dextran-stripped serum, treated as specified in the Results
section before lysis, and then assayed for luciferase activity
following the manufacturer’s instructions (Promega) (16).
To control for transfection efficiency, cells were taken from a
single transfected pool and divided into the different treat-
ment conditions. All firefly luciferase readings were normal-
ized to Renilla luciferase.
Small interfering RNA (siRNA) transfection
HeLa cells were transfected with 10 nM IFI16 siRNA (catalog
no. 4392420, siRNA ID s7138; Ambion, Austin, TX, USA) or
10 nM lamin siRNA (4390771, siRNA ID s82222; Ambion)
using Lipofectamine RNAiMax (Invitrogen) in accordance
with the manufacturer’s instructions. Forty-eight hours later,
cells were treated as specified in the Results section and
processed accordingly.
Immunoblot analysis
Cells were treated as specified in the Results section and
lysed in RIPA buffer (50 mM Tris-Cl, pH 7.4, 1% Nonidet
P-40, 0.25% sodium deoxycholate, 150 mM NaCl, and 1
mM EDTA) containing protease (Calbiochem, San Diego,
CA, USA) and phosphatase inhibitors (Sigma-Aldrich
Corp.). Lysates were electrophoresed on SDS-acrylamide
gels and transferred to 0.2-m nitrocellulose membranes
(Bio-Rad Laboratories, Hertfordshire, UK) overnight at
4°C. Membranes were blocked for 6 h (0.15 M NaCl, 1%
dried milk, and 0.1% Tween 20) and incubated with
primary antibodies (diluted in blocking buffer) overnight
at 4°C. After three 10-min washes (88 mM Tris, pH 7.8;
0.25% dried milk; and 0.1% Tween 20), membranes were
incubated with a species-specific horseradish peroxidase-
conjugated secondary antibody (diluted in wash buffer) for
1 h at room temperature and washed a further 3 times,
each for 10 min. Immunoreactive proteins were visualized
using enhanced chemiluminescence (ECL Advance, GE
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Healthcare). Expression levels were quantified using Im-
ageJ software (http://rsb.info.nih.gov/ij/).
Quantitative RT (qRT)-PCR
After siRNA and dexamethasone (Dex) treatment, total RNA
was prepared from HeLa cells using an RNeasy mini kit with
DNase I digestion (Qiagen, Valencia, CA, USA), and cDNA
was synthesized using a SuperScript III Platinum Two-Step
qRT-PCR kit with SYBR Green (Invitrogen).
Seven Gc-regulated genes were selected from our previous
microarray expression studies. qRT-PCR primer sequences
are available on request. Expression levels were calculated
using the comparative Ct method, normalizing to the glycer-
aldehyde-3-phosphate dehydrogenase control.
Immunofluorescence
Cells were treated as specified and then were fixed with 4%
paraformaldehyde for 30 min at 4°C and permeabilized
(0.02% Triton X-100 in PBS) for 30 min at room temper-
ature. Fixed cells were blocked (1% FCS in PBS) for 4 h at
room temperature with agitation and then in primary
antibody (diluted in blocking buffer) overnight at 4°C.
After three 10-min washes in PBS, cells were incubated in
secondary antibody (diluted in PBS) for 2 h. After three
further 10-min washes, coverslips were mounted using
Vectashield hard-set mounting compound containing the
nuclear DAPI stain (Vector Laboratories). Images were
acquired on a Delta Vision RT (Applied Precision, Issa-
quah, WA, USA) restoration microscope using an 60/
1.42 Plan Apo objective and the Sedat filter set (Chroma
89000; Chroma Technology Corp., Rockingham, VT, USA).
The images were collected using a CoolSNAP HQ (Photo-
metrics, Tucson, AZ, USA) camera with a Z optical spacing
of 0.5 m. Raw images were deconvolved using Softworx
software (Applied Precision, Inc., Issaquah, WA, USA), and
maximum intensity projections of these deconvolved im-
ages were processed using ImageJ.
Immunoprecipitation
Cell extracts (500 g of protein) were precleared with protein
A/G-coated Sepharose beads. These beads were pelleted by
centrifugation (1800 g) and discarded. The supernatant was
incubated with either 5 g of primary antibody or equivalent
IgG from nonimmunized animals and protein A/G-coated
Sepharose beads overnight at 4°C. After incubation, samples
were centrifuged at 1800 g to pellet the protein A/G-coated
Sepharose beads. Supernatants were discarded, the pellets
were washed 3 times in ice-cold PBS and boiled for 5 min in
reducing loading buffer, and the beads were removed before
electrophoresis.
Lung immunohistochemistry
Lung tissue was obtained from 2 patients undergoing
surgery for lung cancer. One patient had a diagnosis of
COPD with a forced expired volume in 1 s (FEV1) of 62%
predicted, an FEV1/forced vital capacity ratio of 0.68, and






Regulator of G-protein signaling 14 RGS14  
Sialyltransferase 4B (-galactosidase -2,3-sialytransferase) SIAT4B 
Bone morphogenetic protein receptor, type II (serine/
threonine kinase) BMPRII  
ATPase, class I, type 8B, member 2 ATP8 B2
Propionyl coenzyme A carboxylase,  polypeptide PCCA 
Elongation of very long chain fatty acids
(FEN1/Elo2,SUR4/Elo3, yeast)-like 1 ELOVL1 
Acidic nuclear phosphoprotein 32 family member E ANP32E
Metallophosphoesterase MPPE1
Amyloid  (A4) precursor protein-binding, family B,
member 1 (Fe65) APBB1  
SMT3 suppressor of mif2 3 homologue 4 SUMO4 
ATPase, class I type 8A member 1 ATP8A1
Down-regulator of transcription 1, TBP-binding
(negative cofactor 2) DR1 
X-prolyl aminopeptidase (aminopeptidase P)-like XPNPEP1 
Cadherin, EGF LAG seven-pass G-type receptor 1 CELSR1
Neural cell expressed developmentally down-regulated 9 NEDD9  
Phosphatidylinositol glycan, class B PIGB 
Interferon, -inducible protein 16 IFI16  
RAB3 GTPase-activating protein RAB3GAP1 
Heterogenous nuclear ribonucleoprotein A1 HNRPA1 
Microarray technology used for transcriptome profiling of lymphocytes from a healthy cohort identified a panel of discriminatory genes that
showed small but significant changes in expression between Gc-sensitive and Gc-resistant groups. In some cases, the genes have been renamed
relative to the original publication to reflect the current annotation within the Affymetrix database, i.e., HEF1 	 NEDD9, MGC5350 	 nuclear
phospho protein, Fe65 	 APBB1, AL031133 	 SMT3, and AL390738 	 HNRP A1. Also, the gene now denoted as MPPE1 was independently
identified twice in the original study (hypothetical protein FLJ11585 and gb:BC002877.1/DEF 	 homo sapiens) (7). Thirteen discriminatory
genes were identified as interacting directly or indirectly with the canonical Gc signaling pathway by Ingenuity Pathways Analysis
(http://www.ingenuity.com). Six of these were selected for further study after literature searches identified potential interactions with Gc
signaling. RGS14, BMPRII, APBB1, NEDD9, and IFI16 were predicted to alter GR function by bioinformatic analysis, and SIAT4B was not.
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a 180-pack/yr smoking history. The other patient had
normal lung function and no smoking history. After in-
formed consent and ethical approval were received, lung
tissues (as far distal to tumor as possible) were fixed in
formalin and paraffin-embedded, and 4-m sections were
cut and mounted onto polysine-coated glass slides. Sections
were dewaxed and rehydrated, and epitope was retrieved
(10 mM trisodium citrate buffer, pH 6.0, for 20 min).
Sections were blocked (1.5% normal goat serum and 0.5%
Triton X-100) before incubation with rabbit polyclonal anti-
IFI16 (Santa Cruz Biotechnology, Inc.) overnight at 4°C.
After detection with Alexa Fluor 488-conjugated goat anti-
rabbit IgG (Invitrogen), sections were washed and incubated
with either anti-human CD3, anti-human GR, or anti-human
CD20 overnight at 4°C. Sections were labeled with Alexa
Fluor 568-conjugated goat anti-mouse IgG (Invitrogen) and
then were washed and counterstained with DAPI (Invitro-
gen). Digital micrographs were obtained using a Nikon Eclipse
80i microscope (Nikon, Tokyo, Japan) equipped with a QImag-
ing digital camera (QImaging, Surrey, BC, Canada) and Im-
agePro Plus 5.1 software (MediaCybernetics, Marlow, UK).
Statistical analysis
Data were analyzed in multiple samples after n 	 3 determi-
nations using the SPSS software package (SPSS Inc., Chicago,
IL, USA) and, where appropriate, are expressed as means 

sd. For reporter gene assays, means were compared by 1-way
ANOVA followed by Dunnett’s post hoc test. For qRT-PCR,
data were analyzed by the Mann-Whitney test, and P  0.05
was considered statistically significant.
RESULTS
Identification of Gc signaling pathway interacting
genes: bioinformatics
The discriminatory genes identified by microarray
analysis (Table 1) were used to generate a “hypothet-
ical network” of genes (Fig. 1). The gene products
were not found to interact directly with each other or
with steroid metabolic pathways; however, 12 genes
(Fig. 1, blue) were identified as interacting with the
GR itself (NR3C1), with GR target genes (IL-6 and
leukemia inhibitory factor), or with genes known to
regulate GR function (RelA and p53). Based on the
above analysis and further interrogation of the liter-
ature, it was possible to highlight the strongest
candidates for further analysis: IFI16 is known to
bind p53 (17), which in turn is capable of binding
the GR to affect its activity. IFI16 also binds to the
androgen receptor to up-regulate both its expression
and activity (18). BMPRII is the ligand-binding part-
ner of the signaling bone morphogenetic protein
receptor type I. Bone morphogenic proteins are
members of the TGF- superfamily, which act on
brain and bone and in development (19). We have
previously identified BMPRII as a modulator of GR
function (7). RGS14 is expressed in both brain and
Figure 1. Bioinformatic analysis of 20 candidate Gc sensitivity modulating genes. Network analysis describing interactions
between genes/gene products from the steroid-sensitive gene list with each other and with other well-characterized genes
defined by canonical Gc metabolic and GR signaling pathways. Blue represents genes/gene products from the steroid-sensitive
gene list and red denotes genes represented on canonical Gc pathways. Connecting lines represent interactions.
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spleen (20, 21) and down-regulates signaling by
heterotrimeric G proteins. Neural cell expressed
developmentally down-regulated 9 (NEDD9) is sub-
ject to tyrosine phosphorylation in response to liga-
tion of 1 integrin (22, 23). The adapter protein
APBB1 (also known as Fe65), can interact directly
with estrogen receptor  (24) and itself is phosphor-
ylated by serum and glucocorticoid-induced kinase 1
(SGK1) (25). Because SIAT4B was not predicted to
interact with GR in this analysis, it was selected for
further analysis as a control gene.
IFI16, BMPRII, and RGS14 affect Gc transactivation
The ability of the selected genes to modulate GR
transactivation was tested in HeLa cells transfected
with the Dex-responsive luciferase reporter, TAT3-
Luc. In line with our previous work, SRC2 and
BMPRII both potentiated GR transactivation, and, in
addition, IFI16, and RGS14 also effectively enhanced
Dex-induced GR transactivation (Fig. 2A). In con-
trast, expression of SIAT4B significantly impaired GR
transactivation (Fig. 2A). Expression of NEDD9 or APBB1
had no effect on GR transactivation. Cells transfected with
increasing amounts of IFI16, BMPRII, or RGS14 showed a
greater enhancement of Dex response, whereas increas-
ing the amount of transfected pcDNA3 or SRC2 was
without effect (Fig. 2A). Notably, neither a reporter gene
with deleted GRE elements nor an unrelated CCAAT/
enhancer-binding protein (C/EBP)-responsive reporter
was regulated by IFI16, BMPRII, or SRC2 (Fig. 2B). After
stable integration of the TAT3-Luc reporter cassette into
HeLa cells, overexpression of SRC2, BMPRII, or IFI16 still
enhanced GR transactivation (Fig. 2C).
Figure 2. Expression of BMPRII, IFI16, and RGS14 in HeLa cells enhances
Gc-induced expression of the TAT3-Luc reporter gene. A) HeLa cells were
transiently cotransfected with 2 g of TAT3-Luc reporter, 0.5 g of Renilla
reporter, and either 0.6 or 1.2 g of SRC2, IFI16, BMPRII, APBB1, RGS14,
SIAT4B, NEDD9, or empty pcDNA3 construct. Cells were incubated for 24 h with
Dex (0.1–10 nM) and assayed for luciferase. B) HeLa cells were transiently
cotransfected with 2 g of either C/EBP-Luc or TAT3GRE-Luc and 0.5 g of
Renilla reporter control reporter gene constructs along with 1.2 g of SRC2, IFI16,
BMPRII, or empty pcDNA3 expression vector. Cells were incubated for 24 h with
Dex (0.1–10 nM) and assayed for luciferase. C) HeLa cells stably expressing
TAT3-Luc were cotransfected with 0.5 g of Renilla construct and SRC2, IFI16,
BMPRII, or empty pcDNA3/CMV SPORT6 construct. Twenty-four hours after
transfection, cells were incubated with Dex (0.1–10 nM) for 16 h before harvest
and luciferase analysis. Graphs depict means 
 sd of triplicate wells, representative of 3 independent experiments. *P 	
0.05, **P 	 0.01 vs. empty vector control. RLU, relative light units.
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IFI16 enhances Gc transrepression of an
NF-B reporter
In HeLa cells, 0.5 ng/ml TNF- maximally activated
an NF-B-Luc reporter gene, and higher concentra-
tions progressively impaired the Gc inhibitory re-
sponse, mimicking the acquired Gc resistance seen in
inflammation loci. (Fig. 3). None of the comodulator
genes had a significant effect. At 5 ng/ml TNF-,
only IFI16 was able to restore Gc repression of NF-B
activity. Under control conditions, Dex repressed 0.5
ng/ml TNF- driven reporter activity by 46%, which
was reduced to 30% repression when the reporter
was driven by 5 ng/ml TNF-. IFI16 overexpression
restored repression (48% repression with 0.5 ng/ml
TNF- compared with 49% repression with 5 ng/ml
TNF-) (Fig. 3). Notably, GR expression was not
affected by treatment with TNF- (data not shown).
IFI16 alters Gc-regulated gene expression via
GR-independent and GR-dependent actions
To explore the role of IFI16 in regulating endoge-
nous GR target genes siRNA specific to IFI16 was
used, with lamin siRNA as a control (Fig. 4A). From
our previous microarray expression studies, 7 Gc-
regulated genes were selected for analysis. IFI16
knockdown altered the baseline expression of 6 of 7
well-characterized GR target genes; with only metallo-
thionein 1X (MT1X) showing no alteration in expres-
sion. FK506 binding protein 5 (FKBP5) expression was
augmented by loss of IFI16, and, in contrast, aspartate
-hydroxylase (ASPH), IL-6 signal transducer (gp130
oncostatin M receptor) (IL6ST), myosin 1B (MYO1B),
glutamate ammonia ligase (glutamine synthase)
(GLUL), and TSC22 domain family 3 (GILZ,
TSC22D3) were suppressed by IFI16 knockdown (Fig.
4B).
FKBP5, MT1X, GLUL, and GILZ were up-
regulated and ASPH, IL6ST, and MY01B were down-
regulated in response to treatment with Dex, which is
in accordance with previous findings (7, 26, 27) (Fig.
4C). FKBP5 and MTIX were dramatically less respon-
sive to Gc in the absence of IFI16, whereas GILZ and
GLUL became more Gc responsive. Loss of IFI16
prevented Dex inhibition of ASPH and indeed in-
creased the transcript abundance. The Gc effects on
IL6ST and MYO1B were not significantly affected by
the IFI16 expression level (Fig. 4C). Most interesting,
increased baseline expression of FKBP5 correlated well
with the impaired induction observed with Gc. Con-
versely, the reduced baseline of GLUL and GILZ gave
rise to a much larger induction in the presence of Gc.
IFI16, BMPRII, SIAT4B, and RGS14 do not affect
GR expression or phosphorylation
GR expression powerfully regulates target cell Gc
sensitivity, and so the expression and regulation of
GR protein were measured. Dex treatment for 24 h
caused a 60% reduction in GR expression. A similar
reduction was observed in cells overexpressing IFI16,
BMPRII, SIAT4B, and RGS14, suggesting that Gc
modulatory effects are not mediated through altered
GR expression or stability (Fig. 5A).
Treatment with Dex also induces rapid phosphorylation
of GR on multiple residues. Cells incubated with 100 nM
Dex for 30 min showed a rapid increase in GR phosphory-
Figure 3. Overexpression of IFI16 enhances Gc-induced repression of
the NRE-Luc reporter gene. HeLa cells were transiently cotransfected
with 2 g of NRE-Luc, 0.5 g of Renilla reporter, and 0.6 g of SRC2,
IFI16, BMPRII, APBB1, RGS14, SIAT4B, NEDD9, or empty pcDNA3
construct. Twenty-four hours after transfection, cells were incubated
with 10 nM Dex and 0.5 or 5 ng/ml TNF for 16 h before luciferase
analysis. Graphs depict means 
 sd of triplicate wells, representative of
3 independent experiments. *P  0.05, **P  0.01 vs. empty vector
control.
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lation at serine 211. The phosphorylation status of GR was
unaffected by overexpression of IFI16, BMPRII, SIAT4B, or
RGS14 (Fig. 5B, C). More detailed time course analysis in
cells overexpressing IFI16 demonstrates no effect of IFI16 in
modulating Dex-induced phosphorylation of GR on either
Ser-211 or Ser-203 (Fig. 5D). Phosphorylation of GR at
Ser-226 was not induced by addition of Dex in these cells.
GR and IFI16 colocalize to the same cellular
compartments in HeLa cells
Endogenous (Fig. 6A) and overexpressed (Fig. 6B)
IFI16 had a heterogeneous intracellular distribution
with some cells demonstrating predominantly nu-
clear expression and others mainly cytoplasmic ex-
pression. It was evident that in cells expressing
predominantly nuclear IFI16, GR tended to localize
within the nucleus also, even in the absence of Dex
(Fig. 6A, B, indicated by arrows). Treatment with Dex
increased nuclear GR, which was also accompanied
by increased nuclear IFI16 (Fig. 6C). Thus, there was
clear overlap of GR and IFI16 subcellular localiza-
tion, both in the absence of ligand and after addition
of Dex (Fig. 6A–C). Although subcellular localization
of either protein does not appear to be exclusively
Figure 4. IFI16 modulates GR regulation of endogenous genes. A) HeLa cells transfected with 10 nM IFI16 or lamin siRNA for
48 h were lysed and immunoblotted for IFI16, GR, or tubulin. Representative images are shown. B, C) HeLa cells were
transfected with 10 nM IFI16 or lamin siRNA, treated with vehicle or 100 nM Dex for 4 h, and then lysed and RNA-processed.
Effect on basal (B) and Gc-regulated (C) expression of 7 GC-regulated genes (ASPH, FKBP5, MT1X, IL6ST, MYO1B, GLUL, and
GILZ) was analyzed by qRT-PCR. Graphs depict means 
 sd of triplicate wells, representative of 3 independent experiments.
*P  0.05, **P  0.01 vs. lamin siRNA control.
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dependent on the other, localization to the same
subcellular compartment does allow for potential
interaction.
GR interacts with a specific IFI16 isoform
HeLa cells transfected with the IFI16 expression
vector were treated with vehicle or Dex for 1 h and
then lysed, and cell extracts were subjected to immu-
noprecipitation with two different antibodies (mouse
and rabbit) to both IFI16 or GR and then to immu-
noblotting for IFI16 and GR. Although evidence for
a direct interaction between GR and IFI16 was ob-
served in samples immunoprecipitated with both GR
antibodies, no GR was immunoprecipitated with ei-
ther IFI16 antibody (Fig. 6D). The GR-IFI16 interac-
tion was unaffected by the presence of ligand (Fig.
6D). Strikingly, both GR antibodies immunoprecipi-
tated the B isoform of IFI16 (Fig. 6E). Neither the GR
nor IFI16 was precipitated by incubation with normal
rabbit or normal mouse IgG.
The ligand-binding domain (LBD) of GR is required
for the potentiation of Gc signaling by IFI16
To assess which domain of GR functionally interacts
with IFI16, two deletant GR constructs were used in
transfection studies with the GR-deficient HEK293
cell line: GRAF1, which lacks the AF1 transactiva-
tion domain and has reduced transactivation poten-
tial, and GR N500, which lacks the LBD and is
constitutively active. IFI16 still potentiated the Dex-
induced transactivation in cells transfected with GR AF1
(Fig. 7A) but not with GR N500 (Fig. 7B). This result suggests
that although the interaction between GR and IFI16 does
not require ligand, the LBD is the domain required for
interaction.
The LBD of GR is required for interaction of GR
and IFI16
To determine which domain of GR is required for
physical interaction with IFI16, full-length GR, GR
AF1, and GR N500 constructs fused to a myc tag were
transfected into the GR-deficient HEK293 cell line. GR
was isolated using a myc antibody, and the precipitate
was immunoblotted for IFI16. Figure 7C demonstrates
that IFI16 binding to GR requires intact LBD. IFI16 was
not precipitated by incubation with normal mouse IgG.
Immunoblotting with a GR antibody raised against the
AF1 domain was used to determine the presence of this
domain in the expressed deletants (Fig. 7C).
Figure 5. Expression and activation of GR is not affected by overexpres-
sion of BMPRII, IFI16, RGS14, or SIAT4B. A, B) HeLa cells were
transiently transfected to overexpress IFI16, BMPRII, RGS14, SIAT4B, or
empty pcDNA3 construct. Cells were then incubated with 100 nM Dex for
either 24 h to examine GR expression (A) or 30 min to examine GR
phosphorylation by immunoblot analysis (B). C) Tubulin was also in-
cluded as a loading control. Representative images are shown. Phosphor-
ylated GR was analyzed using ImageJ, and densitometry from 3 independent experiments was expressed as a ratio of
phospho (P)-GR/tubulin. D) HeLa cells transfected to overexpress IFI16 or empty pcDNA3 construct were incubated with
100 nM Dex for up to 24 h and immunoblotted for GR, P-Ser-203-, P-Ser-211-, and P-Ser-226-GR. Immunoblots for IFI16 and
tubulin are included as controls (CTRL). Representative images are shown.
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IFI16 is expressed in lymphoid follicles in
inflammatory lung disease and is coexpressed
with GR
To explore the possible physiological relevance of IFI16
to GR action, expression was sought in human lung
tissue. As Gcs are frequently used to treat patients with
pulmonary inflammation (28), IFI16 expression was
analyzed in lung tissue from a patient with COPD.
COPD is characterized by the presence of lymphoid
follicles within inflamed lung tissue (29, 30). Expres-
sion of IFI16 was found in the airway epithelium and
lymphoid follicles with mainly nuclear localization.
There was clear coexpression of IFI16 with the T
lymphocyte marker CD3 (Fig. 8A) and with the B
lymphocyte marker CD20 (Fig. 8B), suggesting a poten-
tial for GR-IFI16 interaction within immune cells of
inflamed lung tissue.
Colocalization of IFI16 with GR within the inflamma-
tory cell infiltrate was evident in lung sections from a
patient with a diagnosis of COPD (Fig. 9A). The
number of inflammatory cells seen in the non-COPD
lung is substantially less; however, IFI16/GR colocaliza-
tion can be clearly seen (Fig. 9B).
DISCUSSION
A systems biology approach was used to prioritize our
discriminatory panel of genes for functional analysis.
For 5 of these 6 candidate genes (IFI16, BMPRII, Fe65,
NEDD9, and RGS14), literature searches suggested a
role in influencing Gc action, further supporting the
bioinformatic pathway analysis. A functional effect on
Gc signaling was confirmed in vitro for BMPRII, as
documented previously (7), IFI16, and RGS14. How-
ever, neither APBB1/Fe65 nor NEDD9 was found to
affect transactivation or transrepression. SIAT4B was
included in our in vitro functional screen as a represen-
tative gene not predicted by the bioinformatics to affect
Gc action. However, SIAT4B has been shown to alter
expression and activity of sialyltransferase in inflamma-
tion (31), and therefore was of interest. Despite the
informatic software not predicting this gene to interact
functionally with GR, we found that SIAT4B signifi-
cantly inhibited Gc transactivation in HeLa cells, indi-
cating the necessity for experimental verification of
bioinformatically identified “hits.”
GR expression directly affects Gc sensitivity (32). However,
immunoblot analysis found no effect of the genes on GR
expression levels under basal or post-Gc conditions. Phos-
phorylation at serine 211 occurs rapidly on ligand binding
Figure 6. IFI16 and GR subcellular localization. A, B) HeLa cells
expressing endogenous IFI16 (A) or transfected with 1.2 g of
IFI16 expression vector (B) were fixed and double-labeled with
antibodies specific to GR (green) and IFI16 (red), and nuclei
were counterstained with DAPI (blue). C) Arrowheads identify
cells in which IFI16 and GR are localized to the nucleus. HeLa
cells expressing endogenous IFI16 were incubated with vehicle
or 100 nM Dex for 2 h. Cells were fixed and then were labeled
with antibodies specific to GR (green) and IFI16 (red), and
nuclei were counterstained with DAPI (blue). Arrowhead indi-
cates Dex-treated cells in which GR and IFI16 localize to the
nucleus. D) HeLa cells transfected with IFI16 expression vector
(IFI16) were treated with vehicle or Dex for 1 h and then lysed,
and cell extracts were immunoprecipitated (IP) with two differ-
ent antibodies (rabbit and mouse) for either IFI16 or GR.
Precipitates were immunoblotted (IB) for IFI16 and GR. Samples
immunoprecipitated with mouse or rabbit IgG were included as species-specific immunoglobulin controls. E) Schematic diagram
depicting the exons encoding the three IFI16 isoforms.
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Figure 7. IFI16 interacts with the GR in an LBD-dependent manner. A, B) HEK293 cells were transiently transfected with 2 g
of TAT3-Luc, 0.5 g of Renilla, 1.2 g of IFI16 expression vector, and 1 g of either full-length GR or GR AF-1, which lacks
the AF-1 domain (A), or GR N500, which lacks the LBD (B). After transfection cells were incubated with increasing
concentrations of Dex (0.001–1 nM) for 16 h before analysis. Graphs depict means 
 sd of triplicate wells, representative of 3
independent experiments. *P  0.05, **P  0.01. RLU, relative light units. C) HEK293 cells were transiently transfected with
2 g of full-length GR, GR AF-1, or GR N500 myc fusion proteins and then lysed, and cell extracts were immunoprecipitated
(IP) with an antibody raised against myc. Precipitates were immunoblotted (IB) for myc, IFI16, and GR. Samples immunopre-
cipitated with mouse IgG were included as controls. wt, wild-type. D) Schematic representation of the putative domain structure
of IFI16 protein. The N-terminal domain of IFI16 (solid black) contains several regions important for IFI16 activity, including
the DNA-binding domain (DBD), nuclear localization signal (NLS), pyrin/dapin/PAAD domain (pyrin domain), and site of
phosphorylation by casein kinase 2 (CK2). Checkered regions indicate duplicate HIN 200 domains A and B. These are separated
by a serine-threonine-proline (S/T/P)-rich spacer region (hinge region). IFI16 isoforms arise due to alternative RNA splicing
in exons encoding the S/T/P domain. Numbers identify amino acid residues. LxxLL-like motifs, serine phosphorylation, and
nuclear localization signal are also shown.
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and enhances the interaction of the GR with the DRIP/
TRAP coactivator complex and so is important for function
(33–35). GR Ser-211 phosphorylation was unaltered by ex-
pression of the candidate genes. Furthermore, in cells over-
expressing IFI16 no effect on GR phosphorylation at Ser-203
or Ser-226 was seen.
Only one gene, IFI16, a member of the HIN 200
family of proteins that can modulate cell growth, dif-
ferentiation, and antiviral responses (36–38), signifi-
cantly altered both GR transactivation and transrepres-
sion. Its ability to modulate GR transrepression is of
particular interest, with relevance to acquired changes
in Gc sensitivity seen in inflammation, an effect pre-
dominantly mediated by repression of NF-B activity
(39, 40).
To support our reporter gene studies, we looked at
the effect of IFI16 on endogenous gene expression.
The panel selected comprised known Gc-regulated
genes. We show that IFI16 affects basal expression of
most of these genes, supporting a GR-independent
effect of IFI16 on their expression. Furthermore, we
show that IFI16 directly modulates the effect of Dex on
the 7 genes studied. Therefore, there is evidence for
both direct regulation of GR target gene expression by
independently acting IFI16 and, in addition, an effect
of IFI16 on GR transregulation. MT1X is of particular
interest as its expression is unaffected by alteration in
IFI16 expression, but loss of IFI16 dramatically impairs
Gc induction. Therefore, the IFI16 effect is dependent
on GR transactivation. Taken together, the effects of
IFI16 on GR function suggest widespread changes to
the network of GR-regulated genes.
The gene regulation results show a functional effect
of IFI16 on GR function, and coimmunofluorescence
studies show that IFI16 and GR are colocated in both
cytoplasmic and nuclear compartments. Coimmuno-
precipitation experiments reveal IFI16 interactions
with the GR, both in the presence and absence of GR
ligand. The interaction appears quite specific with the
B isoform of IFI16 being preferentially pulled down by
GR. In our cells there appear to be up to four different
IFI16 isoforms expressed, with very similar molecular
mass. Their identity was confirmed using IFI16 siRNA
studies, and multiple isoforms, arising from differential
splicing, have been reported previously, although func-
tional differences have not been described (41). It is
relevant that the IFI16 B isoform has been reported to
be selectively up-regulated in the inflammatory disease
systemic lupus erythematosus (42). It is possible that
isoform differences discovered here may partly reflect
specificity of the antibodies used, although two differ-
ent IFI16 antibodies were tested for completeness, and
both gave similar results. However, these results further
support a direct effect of IFI16 on GR function, as
suggested by the MT1X gene expression study. Such a
direct interaction may also explain why loss of IFI16
causes a different Gc response for ASPH, FKBP5,
GLUL, and GILZ.
To further dissect out the mechanism of IFI16 action
on the GR domain, deletant GR constructs were exam-
ined. These studies showed that the N-terminal trans-
activation domain (AF1) was unaltered by loss of IFI16,
but that the C-terminal transactivation domain (AF2)
was selectively potentiated by IFI16. AF2 function is
difficult to dissect more precisely, as disruption to the
C-terminal domain also abolishes ligand-binding func-
tion, but it is known that agonist ligands induce a
conformational change to the GR C terminus to open
up an interaction surface for coactivator  helices with
the consensus LxxLL motif (43). However, although
IFI16 contains a series of LxxLL motifs in its N-terminal
pyrin domain (Fig. 7D), it is unlikely that these are
required for GR binding. First, the GR-IFI16 interac-
tion was independent of GR ligand binding, required
to reveal the LxxLL interaction cleft, and second, the
interaction was specific to the IFI16 B isoform, which
differs from the nonbinding A and C isoforms only at
exon 7 and not in the N-terminal pyrin domain. The
mode of action of IFI16 on GR is interesting, but the
ligand independence of the interaction and the colo-
calization of the two proteins in both cytoplasm and
nucleus suggests that whereas direct effects on assembly
and function of the GR occur at its target genes, addi-
tional effects are also likely, as, for example, the cytoplas-
mic crosstalk between GR and protein kinase A (44, 45).
Notably, we were able to show expression of IFI16 in
human COPD lung lymphoid follicles, a relevant site
for Gc action, suggesting that it may be playing a role to
modulate Gc sensitivity in vivo. IFI16 has been docu-
mented previously to be highly expressed in B and T
Figure 8. Expression of IFI16 in human lung. Representative photomicrographs of IFI16 expression in areas of T- and
B-lymphocyte aggregates within human lung tissue. Detection of IFI16 (green) within immune cells of a parenchymal tertiary
lymphoid follicle from a patient with COPD. IFI16 was expressed in CD3 T cells (A) and CD20 B cells (B). Left panels are
low-magnification views; right panels are expanded views.
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Figure 9. Colocalization of IFI16 and GR in human lung. Representative photomicrographs of IFI16 and GR. Lung sections
from a patient with COPD (A) and a nonsmoking individual with normal lung function (B) were subject to immunofluorescence
with GR and IFI16 antibodies. All sections were counterstained with DAPI (blue). Arrows indicate inflammatory cells
coexpressing GR and IFI16. Asterisk indicates single expression of GR or IFI16. Top rows are low-magnification views; bottom
rows are expanded views.
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cells, whereas within healthy lung its expression is
restricted to epithelial cells (46), and GR expression in
the lung is similarly found in epithelium and in lym-
phocytes (47).
The IFI family can also affect inflammation directly
through a conserved DAPIN domain (commonly found
in proteins involved in regulatory pathways that pro-
mote NF-B activation) (48), and indeed the murine
homologue of IFI16 binds and inhibits NF-B function
(49–51).
In this study we report a bioinformatic approach to
discover genes capable of altering GR function. Of the
six genes initially identified only four were found to
have functional effects in our in vitro model systems. It
is possible the others had effects that were too subtle to
be detected or that were GR target gene-specific, but
experimental validation of two-thirds of the proposed
genes supports the validity of such an approach. In
addition, SIAT4B, not predicted by bioinformatic
search to interact with GR, was found to influence GR
transactivation in vitro.
The functional importance of IFI16 for GR-mediated
anti-inflammatory action now needs to be fully ex-
plored. Understanding the mechanism of this interac-
tion may lead to new insights for modulating target
tissue response to Gc and so improve the management
of patients with inflammatory diseases.
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